196 related articles for article (PubMed ID: 25704054)
1. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
[TBL] [Abstract][Full Text] [Related]
3. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Valdez BC; Li Y; Murray D; Champlin RE; Andersson BS
Biochem Pharmacol; 2011 Jan; 81(2):222-32. PubMed ID: 20933509
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
[TBL] [Abstract][Full Text] [Related]
6. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
Valdez BC; Brammer JE; Li Y; Murray D; Teo EC; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Leuk Res; 2016 Aug; 47():100-8. PubMed ID: 27294334
[TBL] [Abstract][Full Text] [Related]
7. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Ji J; Valdez BC; Li Y; Liu Y; Teo EC; Nieto Y; Champlin RE; Andersson BS
Exp Hematol; 2016 Jun; 44(6):458-65. PubMed ID: 26976752
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
Valdez BC; Tang X; Li Y; Murray D; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2018 Nov; 67():49-59.e1. PubMed ID: 30102945
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.
Punt AM; Langenhorst JB; Egas AC; Boelens JJ; van Kesteren C; van Maarseveen EM
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jun; 1055-1056():81-85. PubMed ID: 28445850
[TBL] [Abstract][Full Text] [Related]
10. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
Valdez BC; Murray D; Yuan B; Nieto Y; Popat U; Andersson BS
Oncotarget; 2022; 13():319-330. PubMed ID: 35154579
[TBL] [Abstract][Full Text] [Related]
11. Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.
Rakszawski K; Miki K; Claxton D; Wagner H; Shike H; Mineishi S; Naik S
Int J Hematol; 2018 Sep; 108(3):348-350. PubMed ID: 29542029
[TBL] [Abstract][Full Text] [Related]
12. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.
Valdez BC; Yuan B; Murray D; Ramdial JL; Popat U; Nieto Y; Andersson BS
Oncotarget; 2024 Mar; 15():220-231. PubMed ID: 38484153
[TBL] [Abstract][Full Text] [Related]
13. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.
Valdez BC; Li Y; Murray D; Corn P; Champlin RE; Andersson BS
Leuk Res; 2010 Mar; 34(3):364-72. PubMed ID: 19732952
[TBL] [Abstract][Full Text] [Related]
14. The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
Goto S; Goto H; Yokosuka T
Int J Hematol; 2016 May; 103(5):572-83. PubMed ID: 26886449
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
16. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
[TBL] [Abstract][Full Text] [Related]
18. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines.
Valdez BC; Murray D; Nieto Y; Li Y; Wang G; Champlin RE; Andersson BS
Leuk Lymphoma; 2012 May; 53(5):973-81. PubMed ID: 22023523
[TBL] [Abstract][Full Text] [Related]
19. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.
Valdez BC; Wang G; Murray D; Nieto Y; Li Y; Shah J; Turturro F; Wang M; Weber DM; Champlin RE; Qazilbash MH; Andersson BS
Exp Hematol; 2013 Aug; 41(8):719-30. PubMed ID: 23648290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
